MACH7 TECHNOLOGIES LIMITED (M7T)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

M7T - MACH7 TECHNOLOGIES LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.72
Index:

Mach7 Technologies develops software platforms for the healthcare industry. It specialises in image management systems and patient data management. The company has been listed on the ASX since 2005.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.685

30 Nov
2023

0.025

OPEN

$0.67

3.79%

HIGH

$0.69

234,509

LOW

$0.67

TARGET
$1.42 107.3% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLA . HLS . MDR . MPL . MVF . NHF . PSQ . RHC . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
M7T: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 0.4 - 0.5 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-0.4
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx30.0 M
Book Value Per Share xxxxxxxxxxxxxxx24.8
Net Operating Cash Flow xxxxxxxxxxxxxxx-2.6 M
Net Profit Margin xxxxxxxxxxxxxxx-3.49 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-1.78 %
Return on Invested Capital xxxxxxxxxxxxxxx-1.75 %
Return on Assets xxxxxxxxxxxxxxx-1.30 %
Return on Equity xxxxxxxxxxxxxxx-1.78 %
Return on Total Capital xxxxxxxxxxxxxxx-11.66 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-3.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx4 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx23 M
Price To Book Value xxxxxxxxxxxxxxx2.50

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.4 M
Capex % of Sales xxxxxxxxxxxxxxx1.20 %
Cost of Goods Sold xxxxxxxxxxxxxxx31 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Shaw and Partners

xx/xx/xxxx

1

xxx, xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

01/11/2023

1

Add

$1.54

124.82%

Morgans awaits further positive news flow in FY24 after Mach7 Technologies registered large 1Q contract wins and pipeline expansion, with scale and mix at all-time highs.

The company produced a largely cashflow neutral result in its seasonally weakest period, point out the analysts. There was a record sales order book, up 10 times the previous corresponding period, with sales already representing 70% of FY24 guidance.

FY24 guidance for 20% sales order growth and 15-25% revenue growth was reaffirmed, along with an expectation for growth in revenue greater than for operating expenses.

The Add rating and $1.54 target are unchanged.

FORECAST
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of 1.30 cents.
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of 3.70 cents.
Access Stockbroker Research History >

M7T STOCK CHART

FNArena News on M7T

1
Australian Broker Call *Extra* Edition – Nov 08, 2023

Nov 08 2023 - Daily Market Reports
2
Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023 - Australia
3
Rudi’s View: CSL, ResMed, Domino’s Pizza, Helloworld, Iress and Liontown

Oct 11 2023 - Rudi's View
4
Australian Broker Call *Extra* Edition – Oct 04, 2023

Oct 04 2023 - Daily Market Reports
5
FNArena Corporate Results Monitor – 01-09-2023

Sep 01 2023 - Australia

Latest Healthcare services News

1
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
2
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
3
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
4
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
5
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
6
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
7
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
8
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
9
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
10
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals